|
Dr. Baroudy joined Avance Pharma in early 2004 (acquired by Millenia Hopečs subsidiary, Millenia Hope Biopharma in 2006) and was responsible for leading the company’s drug discovery efforts. He has 25 years of industry/academic experience in basic research, infectious disease drug discovery and virology, Antiviral and Antimicrobial Therapy at the Schering-Ploungh Research Institute, where he spearheaded the successful development of CCR5 antagonists that are currently in human clinical trials as HIV entry inhibitors. Dr. Baroudy earned a place on The Scientific American 50 list as the top Research Leader of 2003 in the Medical Treatment category for this contribution.
Prior to joining Schering-Plough, Dr Baroudy was Director, Division of Molecular Virology at James N. Gamble Institute of Medical Research from 1989 to 1995, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. From 1985 to 1989, Dr. Baroudy worked at the NIH in the Laboratory of Infectious Diseases, the Laboratory of Molecular Oncology and the Laboratory of Biology of Viruses.
Dr. Baroudy received his Ph.D. in Biochemistry from Georgetown University.
| 